Full Text View
Tabular View
No Study Results Posted
Related Studies
Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
This study has been completed.
Study NCT00662337   Information provided by Johnson & Johnson Consumer & Personal Products Worldwide
First Received: March 20, 2008   Last Updated: September 24, 2008   History of Changes

March 20, 2008
September 24, 2008
October 2006
November 2006   (final data collection date for primary outcome measure)
Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUC0-t and AUC0-infinity [ Time Frame: At 15 minutes pre-dose (0 hour), and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 36 and 48 hours post-dose ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00662337 on ClinicalTrials.gov Archive Site
The safety analysis included all subjects who took at least one dose of clinical trial test product and had any follow-up information. Subjects in the safety analysis set were summarized and listed, based on actual treatment received. [ Time Frame: 15 minutes pre-dose (0 hour) through 28 days post-dose ] [ Designated as safety issue: No ]
The safety analysis included all subjects who took at least one dose of clinical trial test product and had any follow-up information. Subjects in the safety analysis set were summarized and listed, based on actual treatment received. [ Time Frame: 15 minutes pre-dose (0 hour) through 28 days post-dose ] [ Designated as safety issue: Yes ]
 
Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
A Randomized, Two-Way Crossover Evaluation of the Bioequivalence Between Two Oral Formulations of Diphenhydramine: ULTRATAB Tablet Versus KAPSEALS Capsule

The purpose of this study is to determine if two formulations of diphenhydramine hydrochloride are bioequivalent.

Subjects were required to observe a ten-hour fast and a one-hour fluid restriction prior to each dosing period.

Subjects were randomized into one of two active treatment groups, received supervised dosing of their treatment with approximately eight ounces of water, and were required to maintain fluid restriction for one hour after treatment. Following the one-hour post-dose fluid restriction, subjects could drink water, but consumer no other food or fluids for four hours post-dose.

Following a seven-day washout period, the comparison treatment was administered according to the same procedure as above.

Phase I
Interventional
Basic Science, Randomized, Open Label, Active Control, Crossover Assignment, Bio-equivalence Study
Nasal Congestion
Drug: Diphenhydramine hydrochloride
Experimental: Diphenydramine HCl
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
36
November 2006
November 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy male and/or female subjects between the ages of 18 and 55 years, inclusive
  • approximately 18 to 30 kg/m2 BMI
  • total body weight at least 55 kg (121 lbs)
  • able to understand and sign the written Informed Consent Form
  • willing to follow the protocol requirements and comply with protocol restrictions

Exclusion Criteria:

  • pregnant or lactating women
  • women of childbearing potential not using acceptable form of contraception 3 months prior to the first dose until completion of follow-up procedures
  • history of allergy, sensitivity, and/or idiosyncratic reaction to Benadryl, diphenhydramine hydrochloride, or diphenhydramine citrate
  • evidence of clinical, dietary or psychiatric deviation from normal that could increase the risk to the subject or research staff or interfere with the interpretation of study results
  • use of licit or illicit drugs
  • participated in any other trials within a specified number of days prior to the first dose of the trial treatment
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00662337
Joyce Hauze/Senior Project Manager, JJCPPW
A2341003
Johnson & Johnson Consumer & Personal Products Worldwide
 
Study Director: Melissa Israel, BS McNeil Consumer Healthcare Division of McNeil-PPC, Inc.
Johnson & Johnson Consumer & Personal Products Worldwide
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP